Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis.
In stage I non-seminomatous testicular cancer, the decision between surveillance and adjuvant chemotherapy rests heavily upon the valuation of quality of life. Decision analysis was used to assess at what relapse rate adjuvant chemotherapy is preferred when patients' and clinicians' evaluations are considered. Probabilities were obtained from the literature and from experts. Evaluations of the disease states were obtained from patients (n = 68) and clinicians (n = 50). Results from the model were compared with a treatment preference question, asking for the relapse rate directly. Adjuvant chemotherapy was preferred at relapse rates above 50% when patient evaluations were used. The evaluations of the disease states had a strong impact on the decision. Using clinician evaluations, adjuvant chemotherapy was preferred at relapse rates above 73%. The relapse rates from the treatment preference question were lower: 46% for patients and 35% for clinicians. The results indicate that when patient preferences are accounted for, adjuvant chemotherapy should be considered more often.
Stiggelbout
A M
AM
Medical Decision Making Unit, Leiden University Hospital K-6-R, The Netherlands.
Kiebert
G M
GM
de Haes
J C
JC
Keizer
H J
HJ
Stoter
G
G
de Wit
R
R
Vermorken
J B
JB
Leer
J W
JW
Kievit
J
J
D001291:Attitude of Health Personnel; D017024:Chemotherapy, Adjuvant; D003661:Decision Support Techniques; D018237:Germinoma / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D008134:Long-Term Care; D008297:Male; D017060:Patient Satisfaction; D019057:Quality-Adjusted Life Years; D012008:Recurrence; D012680:Sensitivity and Specificity; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000628:therapy